Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Mutations in the nucleophosmin 1 ( NPM1 ) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated ( NPM1 mut ) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired NPM1 mut sample...
Gespeichert in:
Veröffentlicht in: | Nature communications 2019-05, Vol.10 (1), p.2031-2031, Article 2031 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Mutations in the
nucleophosmin 1
(
NPM1
) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of
NPM1
mutated (
NPM1
mut
) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired
NPM1
mut
samples obtained at diagnosis and relapse. We find a substantial shift in the genetic pattern from diagnosis to relapse including
NPM1
mut
loss (
n
= 11). To better understand these
NPM1
mut
loss cases, we perform whole exome sequencing (WES) and RNA-Seq. At the time of relapse,
NPM1
mut
loss patients (pts) feature distinct mutational patterns that share almost no somatic mutation with the corresponding diagnosis sample and impact different signaling pathways. In contrast, profiles of pts with persistent
NPM1
mut
are reflected by a high overlap of mutations between diagnosis and relapse. Our findings confirm that relapse often originates from persistent leukemic clones, though
NPM1
mut
loss cases suggest a second “de novo” or treatment-associated AML (tAML) as alternative cause of relapse.
NPM1
gene mutation is a founding event in acute myeloid leukaemia. Here, the authors find that at relapse, some patients lose the
NPM1
mutation and show distinct mutational and gene expression patterns, highlighting a potential route for relapse. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-019-09745-2 |